首页 | 本学科首页   官方微博 | 高级检索  
检索        

sST2联合NT-proBNP评估ARNI干预射血分数中间值的心力衰竭患者预后价值分析
引用本文:李丽,赵文萍.sST2联合NT-proBNP评估ARNI干预射血分数中间值的心力衰竭患者预后价值分析[J].中国循证心血管医学杂志,2021(1):85-89,93.
作者姓名:李丽  赵文萍
作者单位:河北大学附属医院心脏中心
摘    要:目的 探讨可溶性生长刺激因子2(sST2)联合N末端B型利钠肽原(NT-proBNP)评估血管紧张素受体脑啡肽酶抑制剂(ARNI)沙库巴曲缬沙坦(SV)干预射血分数中间值的心力衰竭(HFmrEF)患者全因死亡和心衰再入院的预后价值.方法 入选2018年10月~2020年1月于河北大学附属医院心血管内科住院的HFmrEF...

关 键 词:可溶性生长刺激因子2  N末端脑钠肽前体  射血分数中间值的心力衰竭  预后

Analysis of the prognostic value of sST2 combined with NT-proBNP in evaluating ARNI intervention in heart failure patients with median ejection fraction
Authors:Li Li  Zhao Wenping
Institution:(Heart Center,Affiliated Hospital of Hebei University,Baoding 071000,China;不详)
Abstract:Objective To investigate the prognostic value of soluble growth stimulating expression factor 2(sST2)and N terminal pro B type natriuretic peptide(NT-proBNP)on all-cause death and heart failure rehospitalization in heat failure patients with mid-range ejection fraction(HFmrEF)with sacubitril/valsartan(SV)intervention at real world scenarios.Methods A total of 88 HFmrEF patients who were hospitalized in the Department of Cardiology of the Affiliated Hospital of Hebei University from October 2018 to January 2020 were selected as the research subjects.According to whether patients had clinical endpoint events(all-cause death or heart failure readmission)during follow-up,they were divided into event group(n=21)and non-event group(n=67).The general information of the patients,the results of the first echocardiography,laboratory examination,clinical complications,medication and clinical endpoints were collected.The univariate Cox pmportional hazard model was used to screen the variates that might predict prognosis,and then the covariates with statistical significance were included in the multivariate Cox regression model to analyze the predictive value of baseline sST2 and NT-proBNP on a11-cause death and heart failure rehospitalization.Results During the follow-up period of 6-12 months,2 of the 88 patients died from all causes,19 patients were re-admitted to hospital with worsening heart failure,and were included in the event group,while 67 patients were included in the non-event group.Univariate and multivariate Cox regression analysis results showed that both sST2 and NT-proBNP were predictors of clinical endpoint events in HFmrEF patients(both P<0.05).The ROC curve showed that the AUC of sST2 to predict the clinical endpoint event was 0.728,the best diagnostic cut-off value was 352.86 pg/ml,the sensitivity was 85.7%,and the specificity was 61.2%.The AUC of NT-proBNP predicting the clinical endpoint event is 0.790,the best diagnostic cut-off value is 4255.00 pg/ml,the sensitivity is 100%,and the specificity is 68.7%.The combined detection of the two is more valuable than any single indicator in predicting the clinical endpoint events of the patient,with an AUC of 0.923,a sensitivity of 95.2%, and a specificity of 80.6%. Conclusion sST2 combined with NT-proBNP can early evaluatethe prognosis of heart failure patients with ARNI intervention with median ejection fraction.
Keywords:Soluble growth-stimulating factor 2  N-terminal pro-B-type natriuretic peptide  Heart failure with median ejection fraction  Prognosis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号